Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$56.23 USD
-6.04 (-9.70%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $56.85 +0.62 (1.10%) 7:22 PM ET
3-Hold of 5 3
C Value F Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Viking Therapeutics, Inc. [VKTX]
Reports for Purchase
Showing records 121 - 140 ( 211 total )
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - NASH Weekly: Our Christmas Gift to You!
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q18 Recap - Awaiting Visibility for VK2809 and VK5211
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q18 Results; Project Light to Continue to Brighten on ''2809 and ''5211; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging VK5211 Update; Could Get Interesting Fast; Target Increased to $31
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NASH Weekly: MDGL vs. VKTX Data Comparison Is Not Apples to Apples
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Our Perspectives on VKTX Data and Derivatives for MDGL, GNFT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Tuesday Morning Mic Drop as VK2809 Serves Notice; Target Increased to $28
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.